Table S1: Minimal residual disease definition

<table>
<thead>
<tr>
<th>Time</th>
<th>Pre-TED</th>
<th>CRF, disease specific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before November 2013</td>
<td>1) Was recipient in cytogenetic remission prior to conditioning?</td>
<td>1) Was recipient in cytogenetic remission prior to conditioning?</td>
</tr>
<tr>
<td></td>
<td>2) Was recipient in molecular remission prior to conditioning?</td>
<td>2) Was recipient in molecular remission prior to conditioning?</td>
</tr>
<tr>
<td>November 2013 – July 2017</td>
<td>1) Was recipient in cytogenetic remission prior to conditioning?</td>
<td>1) Was flow cytometry performed for blood/marrow prior to HCT?</td>
</tr>
<tr>
<td></td>
<td>2) Was recipient in molecular remission prior to conditioning?</td>
<td>2) Was disease detected in blood by flow?</td>
</tr>
<tr>
<td></td>
<td>3) Was recipient in flow cytometry-based remission prior to conditioning?</td>
<td>3) Was disease detected in marrow by flow?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4) Molecular markers detected prior to HCT</td>
</tr>
</tbody>
</table>

Table S2: Variables selected a priori for multivariable analysis of outcomes

Main effect: Haplo vs. MSD

Other variables:
- Patient age at HCT: 18-54 vs. 55+
- Patient gender: male vs. female
- Karnofsky performance score: ≥90 vs. <90
- HCT-CI: 0 vs. 1-2 vs. ≥3
- Race: White vs. African American vs. others
- Ethnicity: Hispanic vs. others
- Cytogenetic risk: Favorable vs. intermediate (including normal) vs. poor: MK vs. other poor
- MRD at time of HCT: positive vs. negative
- AML type: De novo vs. secondary/therapy-related
- Conditioning intensity: MA with TBI vs. MA without TBI vs. RI
- Year of HCT: Continuous
- Donor/Recipient gender: F/F vs. M/M vs. F/M vs. M/F
- Donor/Recipient CMV serostatus: +/+ vs. +/- vs. -/+ vs. -/-
- Center effect

AML: Acute myeloid leukemia; CMV: Cytomegalovirus; F: Female; Haplo: Haploidentical; HCT-CI: Hematopoietic cell transplantation-specific comorbidity index; M: Male; MA: Myeloablative; MK: Monosomal karyotype; MRD: Minimal residual disease; MSD: Matched sibling donor; RI: Reduced-intensity; TBI: Total body irradiation